The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Verywell Health on MSN3d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Hosted on MSN6d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback